TY - JOUR
T1 - Preparing for the incoming wave of biosimilars in oncology
AU - Wolff-Holz, Elena
AU - Garcia Burgos, Juan
AU - Giuliani, Rosa
AU - Befrits, Gustaf
AU - De Munter, Johan
AU - Avedano, Luisa
AU - Aitken, Murray
AU - Gonzalez-Quevedo, Rosa
AU - Vyas, Malvika
AU - De Vries, Elisabeth G.E.
AU - Tabernero, Josep
PY - 2018/9/1
Y1 - 2018/9/1
N2 - © Author (s) (or their employer(s)) 2018. With the imminent arrival of oncology biosimilars in the therapeutic paradigm, stakeholders including a clinician, specialist nurse, patient advocate, regulator and economist provide their perspective on optimising the uptake of these new agents in the treatment of cancer. A number of key messages emerge, based on the discussion that took place during a session of the European Society for Medical Oncology's Annual Congress, ESMO Madrid 2017. First, for successful integration of biosimilars into the global healthcare paradigm, informing and educating the full scope of stakeholders, including clinicians, nurses, pharmacists and patients, is primordial. Success is dependent on providing solid evidence and ensuring all voices are heard. Second, for oncology medicines, much can be learnt from the growing experience of approved biosimilars in other disease indications, with success stories for patients, their healthcare providers and healthcare budgets alike. Finally, effective sustainability of the impact on healthcare budgets and the redirection of these savings require education and transparency.
AB - © Author (s) (or their employer(s)) 2018. With the imminent arrival of oncology biosimilars in the therapeutic paradigm, stakeholders including a clinician, specialist nurse, patient advocate, regulator and economist provide their perspective on optimising the uptake of these new agents in the treatment of cancer. A number of key messages emerge, based on the discussion that took place during a session of the European Society for Medical Oncology's Annual Congress, ESMO Madrid 2017. First, for successful integration of biosimilars into the global healthcare paradigm, informing and educating the full scope of stakeholders, including clinicians, nurses, pharmacists and patients, is primordial. Success is dependent on providing solid evidence and ensuring all voices are heard. Second, for oncology medicines, much can be learnt from the growing experience of approved biosimilars in other disease indications, with success stories for patients, their healthcare providers and healthcare budgets alike. Finally, effective sustainability of the impact on healthcare budgets and the redirection of these savings require education and transparency.
KW - biologicals
KW - biosimilars
KW - cancer medicines
KW - monoclonal antibodies
KW - oncology
U2 - 10.1136/esmoopen-2018-000420
DO - 10.1136/esmoopen-2018-000420
M3 - Review article
VL - 3
JO - ESMO Open
JF - ESMO Open
SN - 2059-7029
IS - 6
M1 - e000420
ER -